Technical Analysis for ONCE - Spark Therapeutics, Inc.

Grade Last Price % Change Price Change
grade D 98.18 1.20% 1.16
ONCE closed up 1.2 percent on Thursday, July 18, 2019, on 46 percent of normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Up Down Down
See historical ONCE trend table...

Date Alert Name Type % Chg
1,2,3 Pullback Bullish Bullish Swing Setup 93.99%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 93.99%
Multiple of Ten Bullish Other 93.99%
Overbought Stochastic Strength 93.99%
Down 3 Days in a Row Weakness 93.99%
Earnings Movers Other 92.93%
Multiple of Ten Bullish Other 92.93%
Weak + Overbought Other 92.93%
Inside Day Range Contraction 92.93%
Overbought Stochastic Strength 92.93%

Older signals for ONCE ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Spark Therapeutics, Inc. focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. The company is developing SPK-RPE65, which is in Phase III clinical trial for the treatment of inherited retinal dystrophies, a group of rare blinding conditions caused by non-sex linked, or autosomal recessive, mutations in the RPE65 gene. It is also developing SPK-CHM for the treatment of choroideremia; and preclinical programs in development for the treatment of hemophilia A and neurodegenerative diseases, as well as a pipeline of product candidates targeting rare blinding conditions. The company has collaboration agreement with Pfizer, Inc. for the development and commercialization of SPK-FIX product candidates in its gene therapy program for the treatment of hemophilia B; and development and manufacturing collaboration with Genable Technologies Limited for the manufacture and provision of development advice in the development of Genable's therapeutic product candidate, GT038, to treat rhodopsin-linked autosomal dominant retinitis pigmentosa. The company was founded in 2013 and is based in Philadelphia, Pennsylvania.
Biology Emerging Technologies Gene Therapy Molecular Biology Medical Genetics Neurodegenerative Diseases Blindness Retinitis Pigmentosa Gene Delivery Genetic Diseases Treatment Of Hemophilia Gene Therapy Products Hemophilia A Choroideremia Genetic Disorder Hemophilia B
Is ONCE a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 3 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 114.2
52 Week Low 34.53
Average Volume 526,547
200-Day Moving Average 76.5595
50-Day Moving Average 104.4158
20-Day Moving Average 100.776
10-Day Moving Average 99.081
Average True Range 2.0963
ADX 26.31
+DI 14.4885
-DI 30.0728
Chandelier Exit (Long, 3 ATRs ) 99.1911
Chandelier Exit (Short, 3 ATRs ) 102.24889999999999
Upper Bollinger Band 105.2395
Lower Bollinger Band 96.3125
Percent B (%b) 0.21
BandWidth 8.85826
MACD Line -1.8401
MACD Signal Line -1.6539
MACD Histogram -0.1861
Fundamentals Value
Market Cap 3.07 Billion
Num Shares 31.3 Million
EPS -6.39
Price-to-Earnings (P/E) Ratio -15.36
Price-to-Sales 124.29
Price-to-Book 11.08
PEG Ratio -0.59
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 100.54
Resistance 3 (R3) 100.31 99.30 100.14
Resistance 2 (R2) 99.30 98.70 99.41 100.01
Resistance 1 (R1) 98.74 98.33 99.02 98.97 99.88
Pivot Point 97.73 97.73 97.87 97.84 97.73
Support 1 (S1) 97.17 97.13 97.45 97.40 96.48
Support 2 (S2) 96.16 96.76 96.27 96.35
Support 3 (S3) 95.60 96.16 96.22
Support 4 (S4) 95.83